Boyd Ben J, Khoo Shui-Mei, Whittaker Darryl V, Davey Greg, Porter Christopher J H
Department of Pharmaceutics, Victorian College of Pharmacy, Monash University, 381 Royal Pde, Parkville, Vic. 3052, Australia.
Int J Pharm. 2007 Aug 1;340(1-2):52-60. doi: 10.1016/j.ijpharm.2007.03.020. Epub 2007 Mar 24.
Liquid crystalline phases that are stable in excess water, formed using lipids such as glyceryl monooleate (GMO) and oleyl glycerate (OG), are known to provide a sustained release matrix for poorly water soluble drugs in vitro, yet there has been no report of the use of these materials to impart oral sustained release behaviour in vivo. In the first part of this study, in vitro lipolysis experiments were used to compare the digestibility of GMO with a second structurally related lipid, oleyl glycerate, which was found to be less susceptible to hydrolysis by pancreatic lipase than GMO. Subsequent oral bioavailability studies were conducted in rats, in which a model poorly water soluble drug, cinnarizine (CIN), was administered orally as an aqueous suspension, or as a solution in GMO or OG. In the first bioavailability study, plasma samples were taken over a 30 h period and CIN concentrations determined by HPLC. Plasma CIN concentrations after administration in the GMO formulation were only sustained for a few hours after administration while for the OG formulation, the plasma concentration of cinnarizine was at its highest level 30 h after dosing, and appeared to be increasing. A second study in which CIN was again administered in OG, and plasma samples taken for 120 h, revealed a Tmax for CIN in rats of 36 h and a relative oral bioavailability of 344% when compared to the GMO formulation (117%) and the aqueous suspension formulation (assigned a nominal bioavailability of 100%). The results indicate that lipids that form liquid crystalline structures in excess water, may have application as an oral sustained release delivery system, providing they are not digested rapidly on administration.
使用单油酸甘油酯(GMO)和油酸甘油酯(OG)等脂质形成的、在过量水中稳定的液晶相,已知在体外可为难溶性药物提供缓释基质,但尚无关于使用这些材料在体内实现口服缓释行为的报道。在本研究的第一部分,体外脂解实验用于比较GMO与另一种结构相关脂质油酸甘油酯的消化率,发现油酸甘油酯比GMO更不易被胰脂肪酶水解。随后在大鼠中进行了口服生物利用度研究,其中将一种难溶性药物模型桂利嗪(CIN)以水悬浮液、GMO溶液或OG溶液的形式口服给药。在第一项生物利用度研究中,在30小时内采集血浆样本,并通过高效液相色谱法测定CIN浓度。给予GMO制剂后,血浆CIN浓度仅在给药后持续数小时,而对于OG制剂,桂利嗪的血浆浓度在给药后30小时达到最高水平,且似乎还在上升。第二项研究中再次将CIN以OG形式给药,并采集120小时的血浆样本,结果显示大鼠中CIN的Tmax为36小时,与GMO制剂(117%)和水悬浮液制剂(名义生物利用度设定为100%)相比,相对口服生物利用度为344%。结果表明,在过量水中形成液晶结构的脂质,若在给药后不被快速消化,可能可用作口服缓释给药系统。